<protocol_summary>
<protocol>
<id>136</id>
<no>RYZ101-101</no>
<status>Open</status>
<title>Phase 1b Single Arm, Open-Label Trial of RYZ101 in Combination with Carboplatin + Etoposide + Atezolizumab in Subjects with Somatostatin Receptor Expressing (SSTR+) Extensive Stage Small Cell Lung Cancer (ES-SCLC)</title>
<secondary_protocol_no>Site: 1125</secondary_protocol_no>
<nct_id>NCT05595460</nct_id>
<sponsor_type>Industry</sponsor_type>
<age_group>Adult</age_group>
<treatment_type>Treatment</treatment_type>
<phase>I</phase>
<scope>National</scope>
<disease_site>Lung</disease_site>
<PI>Rineer, MD, Justin</PI>
<institution>Orlando Health Cancer Institute-Downtown</institution>
<eligibility_file id="11754">Subject Eligibility _Screening Checklist for RYZ-101.docx</eligibility_file>
<management_group>Early Phase; Thoracic Oncology</management_group>
</protocol>
<sipVersion>2025.1 Build 10</sipVersion>
<copyright> <a href="https://advarra.com" target="_blank">&copy; 2025 Advarra, Inc.</a> </copyright>
</protocol_summary>